marked.bio

anti-CLDN18.2 antibody · antibody

osemitamab

1 active trials, targeting Claudin 18.2. Not approved for any biomarker on marked.bio yet.

Also known as TST001.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
Claudin 18.2 expression 1 2 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of osemitamab.

  1. Transcenta Therapeutics 1

Trials

1 of 2 trials shown

  1. A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1/2 Transcenta Therapeutics Started 2020Primary completion 2027-06 NCT04495296

    osemitamaboxaliplatincapecitabinepaclitaxelgemcitabinecisplatinnivolumab

    …pansion study: The subjects with positive CDLN18.2 expression in tumor tissue (defined as CLDN18.2 membranous staining ≥1+ in ≥10% of tumor cells by immunohistochemistry (IHC) in the centr…

    Claudin 18.2 expressionAdvanced Cancer